Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study
Standard
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study. / Deterding, Katja; Spinner, Christoph D; Schott, Eckart; Welzel, Tania M; Gerken, Guido; Klinker, Hartwig; Spengler, Ulrich; Wiegand, Johannes; Zur Wiesch, Julian Schulze; Pathil, Anita; Cornberg, Markus; Umgelter, Andreas; Zöllner, Caroline; Zeuzem, Stefan; Papkalla, Armin; Weber, Kristina; Hardtke, Svenja; von der Leyen, Heiko; Koch, Armin; von Witzendorff, Dorothee; Manns, Michael P; Wedemeyer, Heiner; HepNet Acute HCV IV Study Group.
In: LANCET INFECT DIS, Vol. 17, No. 2, 02.2017, p. 215-222.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study
AU - Deterding, Katja
AU - Spinner, Christoph D
AU - Schott, Eckart
AU - Welzel, Tania M
AU - Gerken, Guido
AU - Klinker, Hartwig
AU - Spengler, Ulrich
AU - Wiegand, Johannes
AU - Zur Wiesch, Julian Schulze
AU - Pathil, Anita
AU - Cornberg, Markus
AU - Umgelter, Andreas
AU - Zöllner, Caroline
AU - Zeuzem, Stefan
AU - Papkalla, Armin
AU - Weber, Kristina
AU - Hardtke, Svenja
AU - von der Leyen, Heiko
AU - Koch, Armin
AU - von Witzendorff, Dorothee
AU - Manns, Michael P
AU - Wedemeyer, Heiner
AU - HepNet Acute HCV IV Study Group
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2017/2
Y1 - 2017/2
N2 - BACKGROUND: Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection.METHODS: In this prospective, open-label, multicentre, single-arm pilot study, we enrolled adults (≥18 years) with acute HCV genotype 1 monoinfection from ten centres in Germany. Patients were given ledipasvir (90 mg) plus sofosbuvir (400 mg) as a fixed-dose combination tablet once daily for 6 weeks. The primary efficacy outcome was the proportion of patients with sustained virological response (defined as undetectable HCV RNA 12 weeks after the end of treatment; other primary outcomes were safety and tolerability of ledipasvir plus sofosbuvir. The primary analysis population consisted of all patients who received at least one dose of study drug. Safety was also assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, number NCT02309918.FINDINGS: Between Nov 19, 2014, and Nov 10, 2015, we enrolled 20 patients. Median HCV RNA viral load at baseline was 4·04 log10 IU/mL (1·71-7·20); 11 patients were infected with HCV genotype 1a and nine patients with genotype 1b. All patients achieved a sustained virological response 12 weeks after the end of treatment (20 [100%] of 20 patients). Treatment was well tolerated; there were no drug-related serious adverse events. Up to 12 weeks after treatment, 22 possible or probable drug-related adverse events were reported. There was one serious adverse event, which was judged unrelated to the study drug; one patient was admitted to hospital for surgery of a ruptured cruciate ligament.INTERPRETATION: Treatment for 6 weeks with ledipasvir plus sofosbuvir was well tolerated and highly effective in patients with acute HCV genotype 1 monoinfection. Short-duration treatment of acute hepatitis C might prevent the spread of HCV in high-risk populations.FUNDING: Gilead Sciences, HepNet Study-House/German Liver Foundation, and German Centre for Infection Research (DZIF).
AB - BACKGROUND: Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection.METHODS: In this prospective, open-label, multicentre, single-arm pilot study, we enrolled adults (≥18 years) with acute HCV genotype 1 monoinfection from ten centres in Germany. Patients were given ledipasvir (90 mg) plus sofosbuvir (400 mg) as a fixed-dose combination tablet once daily for 6 weeks. The primary efficacy outcome was the proportion of patients with sustained virological response (defined as undetectable HCV RNA 12 weeks after the end of treatment; other primary outcomes were safety and tolerability of ledipasvir plus sofosbuvir. The primary analysis population consisted of all patients who received at least one dose of study drug. Safety was also assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, number NCT02309918.FINDINGS: Between Nov 19, 2014, and Nov 10, 2015, we enrolled 20 patients. Median HCV RNA viral load at baseline was 4·04 log10 IU/mL (1·71-7·20); 11 patients were infected with HCV genotype 1a and nine patients with genotype 1b. All patients achieved a sustained virological response 12 weeks after the end of treatment (20 [100%] of 20 patients). Treatment was well tolerated; there were no drug-related serious adverse events. Up to 12 weeks after treatment, 22 possible or probable drug-related adverse events were reported. There was one serious adverse event, which was judged unrelated to the study drug; one patient was admitted to hospital for surgery of a ruptured cruciate ligament.INTERPRETATION: Treatment for 6 weeks with ledipasvir plus sofosbuvir was well tolerated and highly effective in patients with acute HCV genotype 1 monoinfection. Short-duration treatment of acute hepatitis C might prevent the spread of HCV in high-risk populations.FUNDING: Gilead Sciences, HepNet Study-House/German Liver Foundation, and German Centre for Infection Research (DZIF).
U2 - 10.1016/S1473-3099(16)30408-X
DO - 10.1016/S1473-3099(16)30408-X
M3 - SCORING: Journal article
C2 - 28029529
VL - 17
SP - 215
EP - 222
JO - LANCET INFECT DIS
JF - LANCET INFECT DIS
SN - 1473-3099
IS - 2
ER -